Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ASNDNASDAQ:ITCINASDAQ:NAMSNASDAQ:ROIV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASNDAscendis Pharma A/S$166.85+1.2%$153.97$111.09▼$169.37$10.17B0.54500,504 shs136,624 shsITCIIntra-Cellular Therapies$131.87$131.22$64.09▼$131.98$14.05B0.691.46 million shsN/ANAMSNewAmsterdam Pharma$18.13+1.7%$19.58$14.06▼$27.29$1.99B-0.01591,852 shs130,552 shsROIVRoivant Sciences$11.35+1.4%$10.35$8.73▼$13.06$8.10B1.255.46 million shs2.23 million shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASNDAscendis Pharma A/S+0.44%+2.31%+6.59%+27.45%+21.32%ITCIIntra-Cellular Therapies0.00%0.00%+0.05%+3.83%+80.00%NAMSNewAmsterdam Pharma+1.77%+9.66%-18.06%-16.88%-18.92%ROIVRoivant Sciences+1.63%+11.45%+7.80%+0.36%+1.45%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationASNDAscendis Pharma A/S2.3649 of 5 stars3.52.00.00.03.01.70.6ITCIIntra-Cellular Therapies2.2878 of 5 stars1.13.00.04.51.11.70.6NAMSNewAmsterdam Pharma3.1773 of 5 stars3.53.00.00.03.64.20.0ROIVRoivant Sciences2.1126 of 5 stars3.51.00.00.03.32.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceASNDAscendis Pharma A/S 2.93Moderate Buy$204.6722.67% UpsideITCIIntra-Cellular Therapies 2.17Hold$109.70-16.81% DownsideNAMSNewAmsterdam Pharma 3.00Buy$43.33139.08% UpsideROIVRoivant Sciences 3.00Buy$17.5054.25% UpsideCurrent Analyst Ratings BreakdownLatest NAMS, ITCI, ROIV, and ASND Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/21/2025ROIVRoivant SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$18.00 ➝ $18.004/16/2025ASNDAscendis Pharma A/SRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$205.004/8/2025NAMSNewAmsterdam PharmaNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$42.00 ➝ $42.004/2/2025ITCIIntra-Cellular TherapiesCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$132.00 ➝ $132.003/18/2025ASNDAscendis Pharma A/SJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$168.00 ➝ $200.003/4/2025ROIVRoivant SciencesCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy3/3/2025NAMSNewAmsterdam PharmaUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$41.002/27/2025NAMSNewAmsterdam PharmaScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Outperform ➝ Sector Outperform$47.00 ➝ $52.002/27/2025NAMSNewAmsterdam PharmaNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$46.00 ➝ $42.002/25/2025ASNDAscendis Pharma A/SCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$170.00 ➝ $200.002/24/2025ITCIIntra-Cellular TherapiesMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Neutral$140.00 ➝ $132.00(Data available from 4/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookASNDAscendis Pharma A/S$363.64M27.98N/AN/A($1.88) per share-88.75ITCIIntra-Cellular Therapies$680.50M20.64N/AN/A$6.15 per share21.44NAMSNewAmsterdam Pharma$45.56M43.69N/AN/A$3.50 per share5.18ROIVRoivant Sciences$122.59M66.04N/AN/A$7.76 per share1.46Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateASNDAscendis Pharma A/S-$409.12M-$7.10N/A695.21N/A-104.54%N/A-39.23%5/1/2025 (Estimated)ITCIIntra-Cellular Therapies-$139.67M-$0.73N/A694.05N/A-14.07%-9.93%-8.38%5/6/2025 (Estimated)NAMSNewAmsterdam Pharma-$176.94M-$2.60N/AN/AN/AN/AN/AN/A5/14/2025 (Estimated)ROIVRoivant Sciences$4.35B-$0.15N/AN/AN/A-119.54%-14.05%-12.81%5/29/2025 (Estimated)Latest NAMS, ITCI, ROIV, and ASND EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025NAMSNewAmsterdam Pharma-$0.45N/AN/AN/A$1.46 millionN/A5/1/2025Q1 2025ASNDAscendis Pharma A/S-$1.56N/AN/AN/A$98.56 millionN/A2/26/2025Q4 2024NAMSNewAmsterdam Pharma-$0.48-$0.95-$0.47-$0.95$3.30 million$12.77 million2/21/2025Q4 2024ITCIIntra-Cellular Therapies-$0.08-$0.16-$0.08-$0.16$205.08 million$199.22 million2/12/2025Q4 2024ASNDAscendis Pharma A/S-$1.32-$0.68+$0.64-$0.68$115.06 millionN/A2/10/2025Q3 2025ROIVRoivant Sciences-$0.24-$0.20+$0.04$0.23$4.75 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthASNDAscendis Pharma A/SN/AN/AN/AN/AN/AITCIIntra-Cellular TherapiesN/AN/AN/AN/AN/ANAMSNewAmsterdam PharmaN/AN/AN/AN/AN/AROIVRoivant SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioASNDAscendis Pharma A/SN/A1.170.84ITCIIntra-Cellular TherapiesN/A7.667.51NAMSNewAmsterdam PharmaN/A10.6110.61ROIVRoivant SciencesN/A37.9137.91Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipASNDAscendis Pharma A/SN/AITCIIntra-Cellular Therapies92.33%NAMSNewAmsterdam Pharma89.89%ROIVRoivant Sciences64.76%Insider OwnershipCompanyInsider OwnershipASNDAscendis Pharma A/S40.00%ITCIIntra-Cellular Therapies2.60%NAMSNewAmsterdam Pharma19.50%ROIVRoivant Sciences7.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableASNDAscendis Pharma A/S64060.97 million36.41 millionOptionableITCIIntra-Cellular Therapies560106.52 million103.56 millionOptionableNAMSNewAmsterdam Pharma4109.82 million74.37 millionOptionableROIVRoivant Sciences860713.55 million657.18 millionOptionableNAMS, ITCI, ROIV, and ASND HeadlinesRecent News About These CompaniesRoivant Sciences Ltd. (ROIV): Among Billionaire Andreas Halvorsen’s Stock Picks With Huge Upside PotentialApril 29 at 12:50 PM | insidermonkey.comIntegrated Wealth Concepts LLC Purchases 41,564 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV)April 29 at 5:40 AM | marketbeat.comRoivant Sciences Ltd. (NASDAQ:ROIV) Position Increased by Tower Research Capital LLC TRCApril 29 at 4:46 AM | marketbeat.comGilder Gagnon Howe & Co. LLC Acquires Shares of 1,162,986 Roivant Sciences Ltd. (NASDAQ:ROIV)April 28 at 6:29 AM | marketbeat.comSyon Capital LLC Buys Shares of 22,814 Roivant Sciences Ltd. (NASDAQ:ROIV)April 28 at 5:36 AM | marketbeat.comRoivant Sciences Ltd. (NASDAQ:ROIV) Shares Sold by First Trust Advisors LPApril 28 at 4:26 AM | marketbeat.comRoivant Sciences Ltd. (NASDAQ:ROIV) Holdings Increased by Two Seas Capital LPApril 27 at 6:28 AM | marketbeat.comBarclays PLC Buys 110,371 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV)April 27 at 3:54 AM | marketbeat.comCredit Industriel ET Commercial Invests $1.77 Million in Roivant Sciences Ltd. (NASDAQ:ROIV)April 26 at 7:30 AM | marketbeat.comRoivant Sciences Ltd. (NASDAQ:ROIV) Stock Holdings Lessened by Adage Capital Partners GP L.L.C.April 26 at 6:32 AM | marketbeat.comInsider Selling: Roivant Sciences Ltd. (NASDAQ:ROIV) COO Sells 100,000 Shares of StockApril 24, 2025 | marketbeat.comBlackBarn Capital Partners LP Increases Stock Holdings in Roivant Sciences Ltd. (NASDAQ:ROIV)April 24, 2025 | marketbeat.comPeak6 LLC Invests $355,000 in Roivant Sciences Ltd. (NASDAQ:ROIV)April 24, 2025 | marketbeat.comCantor Fitzgerald maintains overweight on Roivant Sciences stockApril 23, 2025 | uk.investing.comRoivant Sciences (NASDAQ:ROIV) Receives "Buy" Rating from HC WainwrightApril 23, 2025 | marketbeat.comRoivant Sciences: Primed For Growth With A De-Risked PipelineApril 23, 2025 | seekingalpha.comUn initié de Roivant Sciences a vendu des actions pour une valeur de 1 022 000 dollars, selon un récent dépôt auprès de la SEC.April 23, 2025 | zonebourse.comHC Wainwright Reiterates "Buy" Rating for Roivant Sciences (NASDAQ:ROIV)April 23, 2025 | americanbankingnews.comL’action de Roivant Sciences maintient un objectif de 18$ malgré un remaniement de directionApril 22, 2025 | fr.investing.comLe président de Roivant Sciences, Eric Venker, vend des actions pour 1,02 millionApril 22, 2025 | fr.investing.comCantor Fitzgerald maintient sa recommandation positive sur l’action Roivant SciencesApril 22, 2025 | fr.investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNAMS, ITCI, ROIV, and ASND Company DescriptionsAscendis Pharma A/S NASDAQ:ASND$166.85 +1.97 (+1.19%) As of 02:07 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.Intra-Cellular Therapies NASDAQ:ITCI$131.87 0.00 (0.00%) As of 04/2/2025Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.NewAmsterdam Pharma NASDAQ:NAMS$18.12 +0.30 (+1.65%) As of 02:08 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.Roivant Sciences NASDAQ:ROIV$11.34 +0.16 (+1.39%) As of 02:08 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Coca-Cola Company Stock Can Bubble to New Highs This Year Intel: Good Quarter, Bad Vibes, Guidance Rattles Investors Don’t Be Fooled by the Bounce: The Market Storm Isn’t Over Yet Domino’s Pizza Builds Leverage: Analysts Raise Price Targets 5 Mid-Cap Stocks Insiders Are Buying This Year Alphabet Rebounds After Strong Earnings and Buyback Announcement Occidental’s Hidden Gem: How OxyChem Could Boost Profits T-Mobile US: The Un-Carrier Is an Indisputable Buy on the Dip Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
